SCHEMBL7201067

SCHEMBL7201067

CCOC(=O)C1=COc2ccccc2O1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
ALDH1A1 P00352 5/20 0.45
MAPT P10636 3/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
HSD17B10 Q99714 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MTNR1A P48039 1/20 0.43
CYP1A2 P05177 1/20 0.42
GLA P06280 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.40
AHR P35869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5337504 0.84 PTGS2 (0.47) TSHRALDH1A1MAPTKMT2AMEN1
SCHEMBL9251348 0.81 CA12 (0.49) TSHRALDH1A1MAPTKMT2AMEN1
SCHEMBL8580093 0.81 CA12 (0.49) ALDH1A1MAPTKMT2AMEN1HSD17B10
SCHEMBL30606875 0.81 MTNR1A (0.46) TSHRALDH1A1HSD17B10CA12CA1
SCHEMBL8580296 0.80 MAOB (0.49) ALDH1A1MAPTKMT2AMEN1HSD17B10
SCHEMBL8579581 0.79 KDM4E (0.48) TSHRALDH1A1MAPTKMT2AMEN1
SCHEMBL8580456 0.79 ALDH1A1 (0.41) TSHRALDH1A1MAPTKMT2AMEN1
SCHEMBL8580159 0.78 MAPT (0.39) TSHRALDH1A1MAPTKMT2AMEN1
SCHEMBL8580415 0.78 MAPT (0.47) TSHRMAPTKMT2AMEN1CA12
SCHEMBL8580305 0.78 MAPT (0.47) TSHRMAPTKMT2AMEN1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10139779-A None JP disclosed
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed
US-5807882-A ANTITUMOR AGENTS ADIR ET COMPAGNIE (FR) 1998-09-15 US disclosed
JP-H10139779-A SUBSTITUTED 7,12-DIOXABENZO(A)ANTHRACENE COMPOUND, PRODUCTION THEREOF AND MEDICINAL COMPOSITION CONTAINING THE SAME ADIR 1998-05-26 JP disclosed
US-5439909-A 2-Substituted with amide or thioamide group; antioxidant for lipoproteins, antilipemic agents, anticholesterol agents ADIR ET COMPAGNIE (FR) 1995-08-08 US disclosed
US-5420132-A Antilipemic agents ADIR ET COMPAGNIE (FR) 1995-05-30 US disclosed
WO-1981003172-A1 NOVEL BENZO(1,4)DIOXINS,METHODS FOR THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS CERM CENT EUROP RECH MAUVERNAY (FR) 1981-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 TSHR 263/4885ALDH1A1 486/4885MAPT 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.